Zuluaga-Arias Heyde-Patricia, Alkhakany Mayada, Younus Manal M, Sefiani Houda, Caro-Rojas Angela, Al-Zubiedi Sameh, Albalawi Wafi F, Alshammari Thamir M
Colombian Association of Pharmacovigilance, Bogotá, Colombia.
International Society of Pharmacovigilance - LATAM Chapter, Bogotá, Colombia.
Ther Adv Drug Saf. 2023 Mar 17;14:20420986231159752. doi: 10.1177/20420986231159752. eCollection 2023.
More than 2 years has passed since the pandemic was declared in 2019 due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was later declared to be the pathogen causing coronavirus disease 2019 (COVID-19). During this time, many healthcare systems faced numerous challenges to control the high morbidity and mortality of the disease. Unlike previous pandemics, the actions against this pandemic started quickly on both the global and country levels. These actions were, scientifically, to study the virus as well as transmission process and to develop medications and vaccines against it. Also, we had to protect people from transmission by knowing how best to apply precautionary methods. However, there were some unexpected negative consequences of the pandemic and one of those the World Health Organization (WHO) called 'infodemic'. This term infodemic refers to the manipulation of a population's behavior in the assessment of information (or, more accurately, lack of assessment) related to the use of medications, particularly vaccines. Unfortunately, even with positive development in science, there was limited and often contradictory amount of information on the safety and efficacy profile of drugs and vaccines. Therefore, this made it harder for public health agencies to determine the impact of the incidence of adverse reactions and events associated with interventions such as vaccines. Hence, risk communication needs to be emphasized during any pandemic, as ignoring risk communications to different stakeholders could undermine all well-intended therapeutic interventions. Given this, it is important that the different stakeholders involved (health authorities, societies, healthcare professionals, etc.) assess the different behavioral patterns within their respective populations and propose appropriate strategies to act. Such an approach complement having risk management and communication plans for this and future pandemics. The aim of this article is to explore how information management, risk management, and risk communication during the pandemic can provide valuable lessons for the future.
More than 2 years have gone by since the pandemic was declared in 2019 due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Many challenges have been confronted by the healthcare system during this time to control the high impact of this disease. This pandemic, unlike others that humanity has faced, is characterized by a special feature: today, we have an enormous amount of information only a click away. This situation has been of great benefit to humanity and has allowed the development of science; nevertheless, misinformation (infodemics) has been a major problem, which has revealed the behavior of the population regarding the evaluation of information (or better, lack of assessment) related to the use of medications and particularly of vaccines. Given this, it is important that the different people involved (health authorities, societies, healthcare professionals, etc.) assess the behavior and propose appropriate strategies to act and have plans for this and future pandemics. This article intends to explore from the authors' perspective how information management, risk management, and risk communication during the pandemic can provide valuable lessons for the future.
自2019年因严重急性呼吸综合征冠状病毒2(SARS-CoV-2)宣布大流行以来,已经过去了两年多,该病毒后来被宣布为导致2019冠状病毒病(COVID-19)的病原体。在此期间,许多医疗系统在控制该疾病的高发病率和死亡率方面面临诸多挑战。与以往的大流行不同,针对此次大流行的行动在全球和国家层面迅速展开。从科学角度来看,这些行动包括研究病毒及其传播过程,以及研发针对它的药物和疫苗。此外,我们还必须通过了解如何最好地应用预防方法来保护人们免受传播。然而,这场大流行产生了一些意想不到的负面后果,其中之一就是世界卫生组织(WHO)所称的“信息疫情”。“信息疫情”一词指的是在评估与药物特别是疫苗使用相关的信息(或者更准确地说,缺乏评估)时对人群行为的操纵。不幸的是,即使科学有了积极进展,关于药物和疫苗安全性及有效性的信息数量有限且往往相互矛盾。因此,这使得公共卫生机构更难确定与疫苗等干预措施相关的不良反应和事件发生率的影响。因此,在任何大流行期间都需要强调风险沟通,因为忽视与不同利益相关者的风险沟通可能会破坏所有善意的治疗干预措施。鉴于此,重要的是,所涉及的不同利益相关者(卫生当局、社会、医疗保健专业人员等)评估其各自人群中的不同行为模式,并提出适当的行动策略。这种方法补充了针对此次及未来大流行的风险管理和沟通计划。本文的目的是探讨大流行期间的信息管理、风险管理和风险沟通如何能为未来提供宝贵经验教训。
自2019年因严重急性呼吸综合征冠状病毒2(SARS-CoV-2)宣布大流行以来,已经过去了两年多。在此期间,医疗系统面临诸多挑战以控制这种疾病的高影响。与人类面临的其他大流行不同,此次大流行有一个特殊特征:如今,我们只需点击一下就能获取大量信息。这种情况对人类大有裨益,并推动了科学发展;然而,错误信息(信息疫情)一直是个大问题,它揭示了人群在评估与药物特别是疫苗使用相关的信息(或者更确切地说,缺乏评估)时的行为。鉴于此,重要的是,所涉及的不同人群(卫生当局、社会、医疗保健专业人员等)评估行为并提出适当的行动策略,以及针对此次及未来大流行制定计划。本文旨在从作者的角度探讨大流行期间的信息管理、风险管理和风险沟通如何能为未来提供宝贵经验教训。